Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
about
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionMortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC RegistrySystematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeCase Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes."Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.A comprehensive comparative review of adenosine diphosphate receptor antagonists.Acute coronary syndromes: identifying the appropriate patient for prasugrel.Perioperative antiplatelet management in patients with coronary artery stenting.Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.Antiplatelet therapy: new pharmacological agents and changing paradigms.Cangrelor: a novel intravenous antiplatelet agent with a questionable future.Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention.The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association.ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
P2860
Q34166239-E2738F77-F17D-4657-82CF-6CBDB9928F26Q36833637-0B518F73-AD12-44B7-B680-CCA2283CE4A1Q36841959-525BB0D4-1E38-44D8-8D33-419707F12B30Q37403998-060C60C8-6A1C-43D0-9024-CC5BA0A37915Q37561275-BCCA4D3D-C2A3-4E4B-849E-724A4419CCADQ37973114-E1050A56-C223-4E24-8F80-C55EAF8A24ECQ37995859-AEB3D312-4D50-4D68-B3F3-FA789ABE2CBEQ38012080-334A2B71-D58E-476D-8524-728E9BC9D941Q38025446-CDE6CD34-0262-48E9-BB54-018AF4D5EEA1Q38117743-24239F40-4840-4AAB-BD59-75855B6DEF25Q38239906-343645A8-A5CC-4DEB-B84B-75F79A13230AQ38340126-7BA82AA5-5095-40FD-8F85-97B2D3B2830CQ39010701-ADA704AA-FACD-4611-8D2B-6A028B520DB3Q41026410-7470F65B-51A9-4B23-BEC0-FED34E0E2E94Q43435896-245DABC9-BD92-4604-A648-EE7F3C8CEE17Q48213904-F459DB19-029A-4168-95E1-460B32F963B7Q48761175-F40B5EAD-2D6F-40FB-BA51-E74225ACE898Q52814619-FBBE77FD-CE50-4FF0-ABC3-875785346755Q57764209-B217085B-2F71-445B-8F54-E11149F05437
P2860
Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@en
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@nl
type
label
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@en
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@nl
prefLabel
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@en
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@nl
P2093
P1476
Efficacy and safety of intensi ...... worldwide regulatory agencies.
@en
P2093
Guiseppe Musumeci
Michael Ragosta
Nihar Desai
Sabina A Murphy
Stephen D Wiviott
P304
P356
10.1016/J.AMJCARD.2011.05.020
P407
P577
2011-08-02T00:00:00Z